Patents Assigned to Deutsches Krebsforschungszentrum Stiftung Des
Öffentlichen Rechts
-
Publication number: 20250014882Abstract: An automated system (112) for providing at least one sample (136) for electrospray ionization in a mass spectrometer system (110) is disclosed.Type: ApplicationFiled: December 6, 2022Publication date: January 9, 2025Applicant: Deutsches Krebsforschungszentrum Stiftung des oeffentlichen RechtsInventors: Mogjiborahman Salek, Jonas Foerster, Angelika Beate Riemer
-
Publication number: 20240392388Abstract: The present invention relates to a method of determining the supplier from which a test animal-derived product sample originates, the method comprising the steps of: (a) determining a test methylation profile of one or more pre-selected methylation sites within the genomic material contained in the test animal-derived product sample; and (b) comparing the test methylation profile determined in (a) with a panel of predetermined reference methylation profiles of the same biological taxon of the test animal from which the product sample derives, wherein each of the predetermined reference methylation profiles is from a different reference animal and/or different supplier, wherein if the test methylation profile of (a) is significantly similar to one of the predetermined reference methylation profiles, the test animal-derived product sample is confirmed of originating from a first supplier from which a first reference animal with the predetermined reference profile is obtained.Type: ApplicationFiled: September 2, 2022Publication date: November 28, 2024Applicants: Evonik Operations GmbH, DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES ÖFFENTLICHEN RECHTSInventors: Florian BÖHL, Frank LYKO, Sanjanaa NAGARAJAN, Suki ROY, Sina LYKO-TÖNGES, Geetha VENKATESH, Walter PFEFFERLE
-
Publication number: 20240331864Abstract: The present disclosure relates to a computer-implemented method for cancer diagnosis, comprising: a) selectively sequencing polymers of a biological sample according to at least one target gene site by translocating the polymers through nanopores of a nanopore sequencing system, including: (i) analyzing an initial nucleotide sequence of a first polymer of the biological sample while the first polymer is translocating through a nanopore of the nanopore sequencing system to determine whether the initial nucleotide sequence corresponds to the at least one target gene site; and (ii) continuing the sequencing of the first polymer to obtain measurement data of the first polymer only if the initial nucleotide sequence of the first polymer corresponds to the at least one target gene site: b) determining, based on the measurement data, a biological state of a nucleotide sequence of the first polymer corresponding to the at least one target gene site; and c) classifying a cancer using a classification algorithm based oType: ApplicationFiled: August 4, 2022Publication date: October 3, 2024Applicants: DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OEFFENTLICHEN RECHTS, UNIVERSITAET HEIDELBERG, OXFORD NANOPORE TECHNOLOGIES PLCInventors: Felix SAHM, Martin SILL, Andreas VON DEIMLING, Stefan PFISTER, David JONES, Areeba PATEL, Helin DOGAN, Matt LOOSE, Alexander PAYNE
-
Publication number: 20240197909Abstract: The disclosure relates to immunological compositions (immunostimulants) based on nanoparticles as carrier for adjuvants, optionally in combination with antigens or epitopes, in particular for the use of the compositions for immunoprophylaxis or immunotherapy.Type: ApplicationFiled: May 12, 2021Publication date: June 20, 2024Applicants: LIFE SCIENCE INKUBATOR GMBH & Co. KG, DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES ÖFFENTLICHEN RECHTSInventors: Armin KÜBELBECK, Angelika RIEMER, Sebastian KRUSE, Eva FEIDT, Agnieszka GRABOWSKA, Ellen JUNGLAS
-
Patent number: 11931349Abstract: The present invention relates to a pharmaceutically compatible iron chelator or a prodrug thereof for use in treating and/or preventing cancer in a subject suspected or known to comprise hypoxic cancer cells, and use in treatment and/or prevention of a human papillomavirus (HPV) related lesion. The present invention further relates to a use of an iron chelator or prodrug thereof for inducing senescence in a cancer cell, preferably a hypoxic cancer cell; and to a method for inducing an irreversible proliferation arrest in cancer cells comprising a) contacting said cancer cells with an iron chelator or prodrug thereof and, thereby, b) inducing an irreversible proliferation arrest in said cancer cells.Type: GrantFiled: November 23, 2018Date of Patent: March 19, 2024Assignee: Deutsches Krebsforschungszentrum Stiftung des öffentlichen RechtsInventors: Felix Hoppe-Seyler, Julia A. Braun, Karin Hoppe-Seyler
-
Patent number: 11866495Abstract: The present invention provides recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for human and Macaca fascicularis CEACAM6 (Carcinoembryonic antigen-related cell adhesion molecule 6, CD66c, Non-specific crossreacting antigen, NCA, NCA-50/90), and which do not significantly cross-react with the closely related human CEACAM1, human CEACAM3, and human CEACAM5. The invention further provides methods to generate this kind of antibodies. The antibodies, accordingly, can be used to treat cancer and other disorders and conditions associated with expression of the CEACAM6. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use.Type: GrantFiled: January 29, 2020Date of Patent: January 9, 2024Assignee: Deutsches Krebsforschungszentrum Stiftung des öffentlichen RechtsInventors: Jörg Willuda, Mark Trautwein, Uwe Gritzan, Christoph Freiberg, Frank Dittmer, Dorian Schönfeld, Julian Marius Glück, Jessica Pinkert, Eva-Maria Gutierrez, Sven Golfier, Simon Holton, Philip Beckhove, Yingzi Ge
-
Publication number: 20240000907Abstract: The invention is based on the finding that endoplasmic reticulum (ER) stress signalling is associated with the pathogenesis of liver disorders such fatty liver, cirrhosis and hepatocellular carcinoma (HCC), and others. The invention identifies novel targets for liver disease therapy which are involved in ER stress signalling, and thereby pertains to compounds and compositions for medical uses, screening approaches to identify therapeutics as well as diagnostic approaches for the identification of disorders or the stratification of certain liver disease patient groups. The invention also pertains to the use of immune checkpoint inhibitors in combination with the compounds or compositions and/or in the treatment of endoplasmic reticulum (ER) stress signalling induced liver cancers.Type: ApplicationFiled: November 12, 2021Publication date: January 4, 2024Applicant: Deutsches Krebsforschungszentrum Stiftung des öffentlichen RechtsInventors: Mathias HEIKENWALDER, Xin LI, Pierluigi RAMADORI, Dirk HALLER
-
Patent number: 11851463Abstract: The present disclosure provides immunogenic compositions, such as vaccines, including DNA vaccines, and uses thereof, e.g., which include an annexin core domain to mediate efficient antigen delivery and antigen presentation in order to induce an antigen-specific immune response and/or to treat or prevent infectious diseases and/or cancer.Type: GrantFiled: January 21, 2021Date of Patent: December 26, 2023Assignee: DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES ÖFFENTLICHEN RECHTSInventors: Fatmire Bujupi, Peter Krammer, Heiko Weyd
-
Publication number: 20230406961Abstract: The present invention provides a novel bispecific anti-CD28 antibody format which is bivalent and comprises two CD28 binding sites, and at least one target binding site. The bispecific anti CD28 antibody of the invention is surprisingly advantageous due to its costimulatory activity which is strictly target cell restricted. The bispecific CD28 antibody of the invention is provided for use in the treatment of diseases either alone or in combination with a further bispecific antibody inducing a CD3/T cell receptor signal.Type: ApplicationFiled: November 3, 2021Publication date: December 21, 2023Applicants: Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts, Eberhard Karls Universität TübingenInventors: Helmut SALIH, Gundram JUNG, Martin PFLÜGLER, Latifa ZEKRI, Timo MANZ
-
Patent number: 11806361Abstract: The present invention provides novel compounds that target thrombocyte activity or aggregation capacity through cellular components for the treatment of diseases associated with Non-Alcoholic Fatty Liver Disease (NAFLD). The invention provides these compounds for treating non-alcoholic steatohepatitis (NASH), a progressed stage of NAFL (non-alcoholic fatty liver), in order to avoid the development of liver cirrhosis and Hepatocellular Carcinoma (HCC). Further provided are pharmaceutical compositions, comprising the compounds of the invention, and methods for screening new NASH therapeuticals.Type: GrantFiled: March 31, 2021Date of Patent: November 7, 2023Assignee: DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES ÖFFENTLICHEN RECHTSInventors: Mathias Heikenwälder, Lars Zender, Achim Weber
-
Patent number: 11802285Abstract: The present invention relates to a compound selectively binding to a sensory receptor or selectively altering the expression of a sensory receptor for use in a method for treating or preventing a disease associated with a pathologic cellular cytotoxic T cell (CTL) response. Further, the invention relates to means for detecting a sensory receptor for use in a method for diagnosing cellular resistance against CTL response in a patient. The invention further embraces a method for determining the resistance of a cell against a CTL response in vitro and to a method for identifying agents that influence the response of cells to CTLs.Type: GrantFiled: September 6, 2019Date of Patent: October 31, 2023Assignee: DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES ÖFFENTLICHEN RECHTSInventors: Philipp Beckhove, Michael Boutros, Nisit Khandelwal, Marco Breinig
-
Patent number: 11773164Abstract: The present invention provides recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for human and Macaca fascicularis CEACAM6 (Carcinoembryonic antigen-related cell adhesion molecule 6, CD66c, Non-specific crossreacting antigen, NCA, NCA-50/90), and which do not significantly cross-react with the closely related human CEACAM1, human CEACAM3, and human CEACAM5. The invention further provides methods to generate this kind of antibodies. The antibodies, accordingly, can be used to treat cancer and other disorders and conditions associated with expression of the CEACAM6. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use.Type: GrantFiled: January 29, 2020Date of Patent: October 3, 2023Assignee: Deutsches Krebsforschungszentrum Stiftung des öffentlichen RechtsInventors: Jörg Willuda, Mark Trautwein, Uwe Gritzan, Christoph Freiberg, Frank Dittmer, Dorian Schönfeld, Julian Glück, Jessica Pinkert, Eva-Maria Gutierrez, Sven Golfier, Simon Holton, Philip Beckhove, Yingzi Ge
-
Publication number: 20230272014Abstract: The disclosure relates to a composition of nanoparticles as carrier for HPV-derived immunogenic fragments and the use of the composition for medical purposes, in particular for immunoprophylaxis or immunotherapy. The invention also relates to a vaccine containing the composition and/or nanoparticles.Type: ApplicationFiled: May 12, 2021Publication date: August 31, 2023Applicants: Life Science Inkubator Betriebs GmbH & Co. KG, Deutsches Krebsforschungszentrum Stiftung des öffentlichen RechtsInventors: Armin KÜBELBECK, Angelika RIEMER, Sebastian KRUSE, Eva FEIDT, Agnieszka GRABOWSKA, Ellen JUNGLAS
-
Publication number: 20230257829Abstract: The invention pertains to a method for the identification of the geographic origin of an individual test subject or of an individual group of test subjects, the method comprising the comparison of a test methylation profile obtained from genomic material of the individual test subject or of the individual group of test subjects with one or more predetermined reference methylation profiles each being specific for a distinct geographic origin.Type: ApplicationFiled: July 23, 2021Publication date: August 17, 2023Applicants: Evonik Operations GmbH, DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES ÖFFENTLICHEN RECHTSInventors: Sina TÖNGES, Frank LYKO, Geetha VENKATESH, Ranja ANDRIANTSOA, Fanny GATZMANN, Florian BÖHL, Andreas KAPPEL, Emeka Ignatius IGWE, Frank THIEMANN
-
Patent number: 11718662Abstract: Disclosed is a method of diagnosing multiple sclerosis (MS), wherein a blood sample from a patient is incubated with a DNA-replication associated (REP) protein. The present invention relates to a DNA-replication-associated (Rep) protein for use in the diagnosis of multiple sclerosis (MS), wherein (a) an increased amount of Rep protein or fragments thereof in the sample as compared to an amount in a control sample; or an increased amount of anti-Rep protein antibodies with antigen in a sample from a subject as compared to an amount in a control sample correlates with a diagnosis of MS, wherein the Rep protein is MSBI1 Rep or MSBI2 Rep.Type: GrantFiled: April 5, 2019Date of Patent: August 8, 2023Assignee: DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES ÖFFENTLICHEN RECHTSInventors: Harald Zur Hausen, Ethel-Michele De Villiers-Zur Hausen, Timo Bund, Sebastian Eilebrecht
-
Publication number: 20230165953Abstract: The invention pertains to an immunization scheme for inducing or amplifying an immune response involving Variant Surface Glycoproteins as carriers for antigenic structures against which the immune response is targeted. The invention is based on a specific priming and boosting schedule using the array presented and soluble VSG variants. Surprisingly, the immunization scheme of the invention elicits a strong and long-lasting antibody response in the immunized subject and therefore is applicable in vaccination approaches, immunotherapy and in the production of novel antibodies.Type: ApplicationFiled: April 20, 2021Publication date: June 1, 2023Applicant: Deutsches Krebsforschungszentrum Stiftung des öffentlichen RechtsInventors: Nina PAPAVASILIOU, Gianna TRILLER, Erec STEBBINS, Joseph VERDI
-
Patent number: 11617624Abstract: Disclosed herein is a system for navigated punction, biopsy or ablation comprising a mobile electromagnetic field generator for generating an electromagnetic navigation field which is connected to an apparatus for medical imaging, a needle-like instrument (16), comprising a sterile distal portion (22) and an optionally non-sterile proximal portion (20), a removable protection device (30) for encapsulating the sterile distal portion (22), a sensor (38) suitable for carrying out measurements allowing for determining the position of the sensor (38) within the navigation field, and a sensor carrier (26). The sensor carrier (26) comprises an elongate carrier body (36) having proximal and distal ends. The sensor (38) is attached to or enclosed by said carrier body (36) close to its distal end.Type: GrantFiled: March 6, 2017Date of Patent: April 4, 2023Assignee: Deutsches Krebsforschungszentrum Stiftung des öffentlichen RechtsInventors: Alfred Franz, Lena Maier-Hein
-
Patent number: 11612646Abstract: The present invention provides a novel PSMA binding antibody termed 10B3 and pharmaceutical and diagnostic uses of the antibody 10B3. The PSMA antibody 10B3 does not cross-compete with the state of the art PMSA binding antibody J591 and has a reduced induction of antigen shift compared to J591 and a unique reactivity with squamous cell carcinoma (SCC) cells of different origin.Type: GrantFiled: January 16, 2017Date of Patent: March 28, 2023Assignees: Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts, Eberhard Karls Universität TübingenInventors: Helmut Salih, Fabian Vogt, Gundram Jung, Latifa Zekri-Metref
-
Publication number: 20230032216Abstract: The present invention relates to the use of Interleukin-4-induced gene 1 (IL4I1) as well as metabolites as produced by IL4I1 as marker in diagnosis and therapy of cancer and related metastasis and/or resistance to immunotherapy.Type: ApplicationFiled: December 10, 2020Publication date: February 2, 2023Applicant: Deutsches Krebsforschungszentrum Stiftung des oeffentlichen Rechts Im Neuenheimer Feld 280Inventors: Alexander Boehme, Saskia Trump, Luis Felipe Somarribas Patterson, Ahmed Sadik, Christiane A. Opitz
-
Publication number: 20220406434Abstract: The present invention is in the field of experimental data acquisition. In particular, the present invention relates to a live-cell imaging method and a corresponding system for acquiring experimental data of one or more biological probes. More specifically, the present invention relates to methods and systems for evaluating an optimized concentration trajectory for administration of a drug, in particular a chemotherapeutic drug.Type: ApplicationFiled: October 22, 2020Publication date: December 22, 2022Applicants: DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OEFFENTLICHEN RECHTS, BERLINER INSTITUT FUER GESUNDHEITSFORSCHUNG ZENTRUM DIGITALE GESUNDHEITInventors: Stefan KALLENBERGER, Tim TREIS, Chiara DI PONZIO, Roland ElLS